<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">49022</article-id><article-id pub-id-type="doi">10.7554/eLife.49022</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Predictors of SIV recrudescence following antiretroviral treatment interruption</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-147493"><name><surname>Pinkevych</surname><given-names>Mykola</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-147494"><name><surname>Fennessey</surname><given-names>Christine M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-147495"><name><surname>Cromer</surname><given-names>Deborah</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-147496"><name><surname>Reid</surname><given-names>Carolyn</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-147497"><name><surname>Trubey</surname><given-names>Charles M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-147498"><name><surname>Lifson</surname><given-names>Jeffrey D</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-147499"><name><surname>Keele</surname><given-names>Brandon F</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-10362"><name><surname>Davenport</surname><given-names>Miles P</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4751-1831</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Infection Analytics Program, Kirby Institute for Infection and Immunity</institution>, <institution>University of New South Wales</institution>, <addr-line><named-content content-type="city">Sydney</named-content></addr-line>, <country>Australia</country></aff><aff id="aff2"><institution content-type="dept">AIDS and Cancer Virus Program</institution>, <institution>Frederick National Laboratory for Cancer Research</institution>, <addr-line><named-content content-type="city">Frederick</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-21373"><name><surname>Kirchhoff</surname><given-names>Frank</given-names></name><role>Reviewing editor</role><aff><institution>Ulm University Medical Center</institution>, <country>Germany</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>keelebf@mail.nih.gov</email> (BK);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>M.Davenport@unsw.edu.au</email> (MD);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>25</day><month>10</month><year>2019</year></pub-date><volume>8</volume><elocation-id>e49022</elocation-id><history><date date-type="received"><day>04</day><month>06</month><year>2019</year></date><date date-type="accepted"><day>24</day><month>10</month><year>2019</year></date></history><permissions><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-49022-v1.pdf"/><abstract><p>There is currently a need for proxy measures of the HIV rebound competent reservoir (RCR) that can predict viral rebound after combined antiretroviral treatment (cART) interruption. In this study, macaques infected with a barcoded SIVmac239 virus received cART beginning between 4- and 27-days post-infection, leading to the establishment of different levels of viral dissemination and persistence. Later treatment initiation led to higher SIV DNA levels maintained during treatment, which was significantly associated with an increased frequency of SIV reactivation and production of progeny capable of causing rebound viremia following treatment interruption. However, a 100-fold increase in SIV DNA in PBMCs was associated with only a 2-fold increase in the frequency of reactivation. These data suggest that the RCR can be established soon after infection, and that a large fraction of persistent viral DNA that accumulates after this time makes relatively little contribution to viral rebound.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HHSN261200800001E</award-id><principal-award-recipient><name><surname>Fennessey</surname><given-names>Christine M</given-names></name><name><surname>Reid</surname><given-names>Carolyn</given-names></name><name><surname>Trubey</surname><given-names>Charles M</given-names></name><name><surname>Lifson</surname><given-names>Jeffrey D</given-names></name><name><surname>Keele</surname><given-names>Brandon F</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>1052979</award-id><principal-award-recipient><name><surname>Pinkevych</surname><given-names>Mykola</given-names></name><name><surname>Cromer</surname><given-names>Deborah</given-names></name><name><surname>Davenport</surname><given-names>Miles P</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>1149990</award-id><principal-award-recipient><name><surname>Pinkevych</surname><given-names>Mykola</given-names></name><name><surname>Cromer</surname><given-names>Deborah</given-names></name><name><surname>Davenport</surname><given-names>Miles P</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>1080001</award-id><principal-award-recipient><name><surname>Davenport</surname><given-names>Miles P</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Animals were cared for in accordance with the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) standards in an AAALAC-accredited facility and all procedures were performed according to protocols approved by the Institutional Animal Care and Use Committee of the National Cancer Institute (Assurance #A4149-01). Animal care was provided in accordance with the procedures outlined in the &quot;Guide for Care and Use of Laboratory Animals&quot;. Reference numbers associated with the ethical approval are AVP047 and AVP058.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Source data files have been provided for Figures.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Fennessey CM</collab><collab>Pinkevych M</collab><collab>Immonen TT</collab><collab>Reynaldi A</collab><collab>Venturi V</collab><collab>Nadella P</collab><collab>Reid C</collab><collab>Newman L</collab><collab>Lipkey L</collab><collab>Oswald K</collab><collab>Bosche WJ</collab><collab>Trivett MT</collab><collab>Ohlen C</collab><collab>Ott DE</collab><collab>Estes JD</collab><collab>Del Prete GQ</collab><collab>Lifson JD</collab><collab>Davenport MP</collab><collab>Keele BF</collab></person-group><year iso-8601-date="2017">2017</year><source>Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy.</source><ext-link ext-link-type="uri" xlink:href="doi: 10.1128/JVI.02092">doi: 10.1128/JVI.02092</ext-link><comment>https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006359#sec025</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-49022-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>